spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Mallinckrodt plc 

 HSMN NewsFeed - 12 Jan 2023
Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2022
Mallinckrodt Announces Appointment of Lisa French as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2021
Mallinckrodt Provides Regulatory Update on StrataGraft(R)
Devices Dermatology FDA
 HSMN NewsFeed - 16 Nov 2020
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience
Biopharmaceuticals
 HSMN NewsFeed - 10 Aug 2020
Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft(R) Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns
Biopharmaceuticals Regenerative Medicine FDA
 HSMN NewsFeed - 6 Apr 2020
Mallinckrodt Initiates Rolling Submission of Biologics License Application for StrataGraft(R) Regenerative Skin Tissue to U.S. Food and Drug Administration
Regenerative Medicine FDA
 HSMN NewsFeed - 12 Mar 2020
Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2020
Mallinckrodt Announces Agreement in Principle for Global Opioid Settlement and Associated Debt Refinancing Activities
Biopharmaceuticals Litigation
 HSMN NewsFeed - 23 Sep 2019
Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft(R) Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns
Regenerative Medicine
 HSMN NewsFeed - 15 Aug 2019
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2019
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2019
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 May 2019
Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders
Biopharmaceuticals Generics
 HSMN NewsFeed - 21 May 2019
Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar(R) Gel
Biopharmaceuticals Reimbursement Litigation
 HSMN NewsFeed - 6 May 2019
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax(R) (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2019
Data on Impact of Revised Consensus Recommendations on Time to Treatment and Serum Creatinine (SCr) at Treatment Start for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Presented at the 2019 International Liver Congress(TM) (EASL)
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2019
Mallinckrodt Completes Full Enrollment of its Phase 3 Clinical Trial for StrataGraft(R) Regenerative Skin Tissue
Devices Regenerative Medicine Wound Care
 HSMN NewsFeed - 18 Mar 2019
Bryan Reasons Joins Mallinckrodt as the Company's Chief Financial Officer (CFO)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2018
Mallinckrodt And NPXe Announce First Patient Enrolled In Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Oct 2018
U.S. FDA Announces Joint Advisory Committee Review of Mallinckrodt's Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone(R) (Oxycodone Hydrochloride)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 23 Aug 2018
Mallinckrodt And NPXe Announce FDA Fast Track Designation For Phase 3 Trial Of Inhaled Xenon Gas Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2018
Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2018
Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2018
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Mar 2018
Mallinckrodt Completes Sale Of RECOTHROM(R) And PREVELEAK(R) To Baxter
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Feb 2018
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2018
Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft(TM)C9T1 Skin Tissue
Devices Wound Care
 HSMN NewsFeed - 13 Feb 2018
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Feb 2018
Mark Casey Joins Mallinckrodt as General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Dec 2017
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Dec 2017
Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Oct 2017
Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Jul 2017
U.S. FDA Designates Mallinckrodt's StrataGraft(R) as Regenerative Medicine Advanced Therapy
Regenerative Medicine FDA
 HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2016
Mallinckrodt Builds UK Presence With New Global Corporate Headquarters in Staines-upon-Thames
Biopharmaceuticals
 HSMN NewsFeed - 1 Sep 2016
Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
Devices Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 25 Aug 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen(R) Depot IND Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Aug 2016
Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 1 Feb 2016
Mallinckrodt Completes Acquisition Of Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
Devices Surgery Acquisitions
 HSMN NewsFeed - 30 Oct 2015
Mallinckrodt's INOmax(R) Approved In Australia And Japan For Pulmonary Hypertension In Conjunction With Heart Surgery
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 May 2014
Mallinckrodt Pharmaceuticals’ New Drug Application Accepted for Review by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Mar 2014
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Feb 2014
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Oct 2013
Mallinckrodt Pharmaceuticals Announces Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2013
Covidien Completes Separation of Pharmaceuticals Business
Biopharmaceuticals Devices Mergers & Acquisitions
 HSMN NewsFeed - 24 May 2013
Covidien Board of Directors Approves Separation of Pharmaceuticals Business and Declares Dividend of Mallinckrodt Ordinary Shares
Biopharmaceuticals
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.